Home Blog Page 1658

Fosun International Honored with TVB’s Highest Accolade, “Outstanding ESG Award”

By
Advertorial Desk
-

HONG KONG, Dec. 22, 2025 /PRNewswire/ — On 19 December 2025, the TVB ESG Awards 2025 Presentation Ceremony, hosted by Television Broadcasts Limited (“TVB”), was held at the Hong Kong Convention and Exhibition Center. Fosun International was honored with the highest accolade, the “Outstanding ESG Award”, as well as awards for “Best in ESG Practices” and “Best in ESG Report”.

Mr. Wong Wai Lun, Michael, GBS, JP, Deputy Financial Secretary of the Government of the Hong Kong Special Administrative Region (SAR), Mr. Siu Sai Wo, General Manager (Business Operations) of TVB and Dr. Lawrence Cheung Chi-chong, Chief Technology Officer of Hong Kong Productivity Council served as officiating guests at the awards ceremony and jointly presented the “Outstanding ESG Award” to Fosun International.

TVB pointed out that Fosun International’s recognition with the “Outstanding ESG Award”, “Best in ESG Practices” and “Best in ESG Report” is well-deserved. After more than 30 years of development, Fosun has developed into a large global company with operations spanning healthcare, tourism, consumption, and insurance. With a robust global industrial ecosystem, Fosun operates responsibly in over 40 countries and regions, actively contributing to public welfare and creating sustainable value worldwide.

TVB highlighted that the awards recognize Fosun International’s outstanding performance in environmental, social, and governance (ESG) and sustainability, while affirming its excellent achievements in ESG over the past year. Each award is presented to the top three scorers in their respective categories, with organizations excelling in both “ESG Practices” and “ESG Report” eligible for the highest accolade, the “Outstanding ESG Award”.

In addition to Fosun International, other recipients of TVB’s highest accolade, the “Outstanding ESG Award”, are all organizations that have demonstrated excellence in ESG. These include government statutory bodies, major public utilities, and well-known companies such as the Airport Authority Hong Kong, MTR Corporation, Schneider Electric, China State Construction Development Holdings Limited, and Riskory Consultancy Limited.

Ms. Angel Sze, Company Secretary and Head of ESG Management Committee of Fosun International, accepted the “Outstanding ESG Award” on behalf of the company and subsequently joined representatives from other award-winning organizations in a panel discussion to share Fosun International’s ESG practices and achievements.

Driven by innovation, committed to social contribution

During the discussion, Angel Sze remarked, “Fosun remains committed to innovation-driven development and globalization. Since its establishment, Fosun has stayed true to its original aspiration of ‘Contribution to Society’, striving to create positive societal impact through its operations. Taking our Health segment as an example, we target original innovation to address unmet clinical needs. By continuously strengthening our independent R&D and innovation capabilities, we strive to deliver higher-quality, more accessible, and more affordable medicines and services to patients.”

Fosun adheres to an innovation-driven strategy, and the anticancer drugs developed by its Health segment have widely benefited cancer patients. Among them, HANSIZHUANG, an innovative anti-PD-1 monoclonal antibody independently developed by Fosun, is the world’s first anti-PD-1 monoclonal antibody approved for the first-line treatment of small cell lung cancer (SCLC). To date, it has been approved for marketing in nearly 40 countries and regions, including China, the European Union, the United Kingdom, Singapore, and India.

Since the beginning of this year, Fosun has achieved multiple breakthroughs in the field of innovative drugs. HLX43, a PD-L1-targeting antibody-drug conjugate (ADC), is undergoing clinical studies for solid tumors such as non-small cell lung cancer and thymic carcinoma in countries including China, the United States, and Australia. Currently, no PD-L1 ADC has been approved globally, positioning HLX43 as a potential highly effective and safe broad-spectrum anticancer drug.

On 7 December, the National Healthcare Security Administration (NHSA) and the Ministry of Human Resources and Social Security (MOHRSS) released the 2025 national medical insurance drug list, which includes multiple marketed products from Fosun Pharma. Moreover, the highly anticipated inaugural edition of the commercial insurance innovative drug list was unveiled, featuring Fosun Pharma’s CAR-T cell therapy Yi Kai Da (ejilunsai injection). The successful inclusion of innovative drugs underscores national support for pharmaceutical innovation and paves the way for market promotion and patient access.

Fosun’s innovation capabilities have also received high recognition from global pharmaceutical companies. On 9 December, Fosun Pharma announced that its subsidiary had entered into a license agreement with Pfizer, granting Pfizer exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient.

At the same time, Fosun actively integrates global resources to accelerate the introduction of cutting-edge medical technologies in China, enhancing the accessibility and affordability of medical technologies. By the end of September 2025, over 480 Da Vinci surgical systems had been installed in more than 370 hospitals across the Chinese mainland, Hong Kong SAR, and Macau SAR, collectively serving over 810,000 patients.

Centering on “Health” as a global public issue, Fosun launched the Rural Doctors Program in 2017. Since its launch, the Program has supported 25,000 rural doctors and benefited 3 million rural families. It was honored as one of the United Nations Global Compact’s “20 Cases of Private Sector’s Sustainable Development in China for 20 Years”, earning international recognition as a model for empowering rural healthcare.

Actively responding to climate change and attaching great importance to biodiversity conservation

With climate change being one of the most severe long-term risks, Fosun recognizes the importance of global cooperation to tackle this challenge. Fosun remains committed to advancing China’s “dual carbon” goals by promoting carbon neutrality and energy conservation and emission reduction. In 2021, Fosun made a commitment to society – “strive to peak carbon emissions by 2028 and achieve carbon neutrality by 2050”. Fosun has formulated strategies for climate change mitigation and adaptation to align with the 1.5°C temperature control target set in the Paris Agreement.

The Group also actively encourages its member companies to carry out climate actions. In 2024, the Bund Finance Center (BFC), the Group’s main office location in Shanghai and a landmark in Shanghai, was successfully included in Shanghai’s first batch of carbon peaking and carbon neutrality pilot demonstration projects, becoming the only large-scale commercial complex exceeding 200,000 square meters on the list.

In 2024, Fidelidade, Fosun’s insurance company in Portugal, established the Impact Center For Climate Change (ICCC), a knowledge center dedicated to climate change research. Through collaborations with external entities, including universities, research centers, and public institutions, it provides scientific insights on the impacts of climate change on society, particularly in the insurance industry.

In addition to actively addressing climate change, Fosun also places great importance on biodiversity conservation. Since 2018, the Lost Chambers Aquarium at Atlantis Sanya, a subsidiary of Fosun Tourism Group (FTG), has been dedicated to rescuing and rehabilitating sea turtles in Hainan Province and its surrounding waters. As of 2024, the aquarium had rescued 24 sea turtles and held 6 sea turtle release events since its opening, returning 10 rehabilitated turtles to the ocean.

On 28 November, FTG hosted “Fosun Holiday Horizon 2026” at Atlantis Sanya, where it signed a partnership agreement with the Nanjing Institute of Environmental Sciences (NIES) of the Ministry of Ecology and Environment (MEE). The two parties will incorporate biodiversity conservation and habitat creation into Club Med resorts, jointly developing China’s first “biodiversity resort” centered on the concept of “harmonious coexistence between humans and nature”.

Empowering a sustainable future through globalization and innovation

Looking ahead, Fosun will remain focused on its core businesses, step up innovation efforts, and firmly advance its globalization strategy, creating greater value for shareholders, employees and society. At the same time, Fosun will continue to closely follow global sustainability trends, continuously refine its ESG management, actively respond to national strategies, ensure information security, promote technology innovation, implement “dual carbon” goals, participate in public welfare undertakings, and protect employees’ rights and interests. Leveraging the resources and advantages of its global industrial ecosystem, Fosun endeavors to make a greater impact on sustainable development and continuously contribute to a better world.

Changsoft I&I Expands Presence in Japan Through Local Joint Venture and BIM Localization

By
Advertorial Desk
-

TOKYO and SEOUL, South Korea, Dec. 22, 2025 /PRNewswire/ — Changsoft I&I, a provider of Building Information Modeling (BIM) solutions for the construction industry, is expanding its presence in Japan through a locally integrated joint venture strategy focused on alignment with Japanese standards and construction practices.

Founded in 2008, Changsoft I&I develops BIM software that integrates design, construction, and maintenance data into a single 3D model. Its solutions automatically convert 2D architectural drawings into detailed 3D structural models and precisely calculate quantities for reinforcement, concrete, and formwork, including advanced reinforcement detailing. These capabilities support improved accuracy and efficiency across complex construction projects.

As part of its international growth strategy, Changsoft I&I identified Japan as a key market due to sustained urban redevelopment activity and demand for advanced construction technologies. Recognizing the importance of local collaboration, the company chose a joint venture model rather than direct market entry to ensure close alignment with local technical standards and industry practices.

In June 2023, Changsoft I&I established BnB Solutions, a joint venture with BSI, a Japan-based engineering venture originating from Tokyo Institute of Technology. Formed with equal ownership, the joint venture operates as a locally positioned entity responsible for product localization, customer engagement, and market development in Japan. The JV was supported by an overseas expansion assistance program jointly operated by Korea’s Ministry of Science and ICT, NIPA, and GDIN, providing structured support for legal, intellectual property, and market entry activities.

A core priority for BnB Solutions has been the localization of Changsoft I&I’s BIM solutions to fully conform with Japanese structural design standards, terminology, documentation formats, and construction workflows. While construction regulations may appear similar across markets, differences in design logic and on-site processes required comprehensive redevelopment. Over nearly one year, the joint venture refined the software through multiple development stages, completing a Japan-optimized version in July last year.

Among the localized features is an automated function that detects and visually identifies rebar interference during the reinforcement detailing phase. This issue has traditionally required manual correction on construction sites. By enabling early identification of interference points, the solution helps reduce rework and supports more efficient coordination between design and construction teams. The functionality has drawn growing interest from Japanese construction and engineering firms.

BnB Solutions is currently engaged in discussions with multiple Japanese companies, with initial purchase requests already received. The joint venture aims to secure approximately ten client companies by March next year and establish a stable revenue base in the Japanese market.

Changsoft I&I’s COO Jongeun Park stated, “Through the joint venture, we can work as a locally aligned partner and adapt our solutions to established standards. We aim to support more efficient and reliable construction processes through long-term collaboration.”

Building on its progress in Japan, Changsoft I&I plans to extend its joint venture–based expansion model to additional regions, while continuing to prioritize locally grounded partnerships and sustainable growth.

CNOOC Limited Brings On-stream Xijiang Oilfields 24 Block Development Project

By
Advertorial Desk
-

HONG KONG, Dec. 22, 2025 /PRNewswire/ — CNOOC Limited (the “Company”, SEHK: 00883 (HKD Counter) and 80883 (RMB Counter), SSE: 600938) today announces that Xijiang Oilfields 24 Block Development Project has commenced production.

The project is located in the shallow water of the Pearl River Mouth Basin. The development of the project mainly leverages the adjacent existing facilities of the Huixi Oilfields, with addition of a new unmanned wellhead platform. 10 development wells are planned to be commissioned. The project is expected to achieve a plateau production of approximately 18,000 barrels of oil equivalent per day in 2026. The oil property is light crude.

The new Xijiang 24-7 platform is China’s first unmanned offshore platform for high-temperature fluid cooling and export. The temperature control system reduces the impact of high temperatures on subsea pipelines, thereby ensuring stable and continuous production.

CNOOC Limited holds 100% interest in this project and is the operator.

— End —

Notes to Editors:

More information about the Company is available at https://www.cnoocltd.com.

*** *** *** ***

This press release includes forward looking information, including statements regarding the likely future developments in the business of the Company and its subsidiaries, such as expected future events, business prospects or financial results. The words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify such forward-looking statements. These statements are based on assumptions and analyses made by the Company as of this date in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company currently believes are appropriate under the circumstances. However, whether actual results and developments will meet the current expectations and predictions of the Company is uncertain. Actual results, performance and financial condition may differ materially from the Company’s expectations, including but not limited to those associated with macro-political and economic factors, fluctuations in crude oil and natural gas prices, the highly competitive nature of the oil and natural gas industry, climate change and environmental policies, the Company’s price forecast, mergers, acquisitions and divestments activities, HSSE and insurance policies and changes in anti-corruption, anti-fraud, anti-money laundering and corporate governance laws and regulations.

Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements. The Company cannot assure that the results or developments anticipated will be realised or, even if substantially realised, that they will have the expected effect on the Company, its business or operations.

*** *** *** ***

For further enquiries, please contact:

Ms. Cui Liu
Media & Public Relations
CNOOC Limited
Tel: +86-10-8452-6641
Fax: +86-10-8452-1441
E-mail: mr@cnooc.com.cn

Mr. Cheng Yao
Ever Bloom (HK) Communications Consultants Group Limited
Tel：+852 5540 0725
Fax：+852 2111 1103
Email: cnooc.hk.list@everbloom.com.cn

 

Samsung to Host Series of Tech Forums at CES 2026

By
Advertorial Desk
-

Forum discussions will feature a moderated panel of experts from across the technology industry to explore the latest trends in AI, Home Appliances, Services and Design

SEOUL, South Korea, Dec. 22, 2025 /PRNewswire/ — Samsung Electronics Co., Ltd. today announced that it will host a series of four moderated Tech Forum panel discussions at CES 2026, to highlight industry trends and unveil its distinct AI vision and strategy.

Samsung to Host Series of Tech Forums at CES 2026
Samsung to Host Series of Tech Forums at CES 2026

Samsung’s Tech Forums will be held Jan. 5–6 at Samsung’s dedicated exhibition space in the Latour Ballroom at the Wynn Las Vegas. The company will host a total of four moderated panels covering AI, Home Appliances, Services and Design. Samsung executives along with partners, academics, media and industry analysts will participate in each session by topic:

  • When Everything Clicks: How Open Ecosystems Deliver Impactful AI (Jan. 5, 9:00 AM) —  Yoonho Choi, Digital Appliances Business, Samsung Electronics (Chair, Home Connectivity Alliance)
    Description: Collaborating smart home innovators hold an open discussion on the necessity of cross-industry partnership and what it takes for meaningful smart home technology to be woven into daily living.
  • In Tech We Trust? Rethinking Security & Privacy in the AI Age (Jan. 5, 2:00 PM) — Shin Baik, Group Head, AI Platform Center, Samsung Electronics
    Description: Experts in security and AI examine the science of trust and how transparency and secure systems can spark a meaningful change for AI adoption.
  • FAST Forward: How Streaming’s Next Wave is Redefining Television (Jan. 5, 4:00 PM) — Salek Brodsky, Executive Vice President, Visual Display Business, Samsung Electronics
    Description: Leaders in TV and entertainment explore the next wave of streaming, including free ad-supported streaming television (FAST), hybrid models and creator-led channels to shape a more interactive future.
  • The Human Side of Tech: Designing a Future Worth Loving (Jan. 6, 1:00 PM) — Mauro Porcini, President and Chief Design Officer, DX Division, Samsung Electronics
    Description: Design leaders urge the tech industry to look beyond minimalist, spec-driven approaches toward more expressive, human-centered design shaped by new materials, AI and creativity.

In covering the latest trends in technology and daily living, the Technology Forum discussions will serve as a complement to the company’s latest product innovations, which will be showcased at the Samsung Exhibition Zone at the Wynn from Jan. 5–7.

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, digital signage, smartphones, wearables, tablets, home appliances and network systems, as well as memory, system LSI and foundry. Samsung is also advancing medical imaging technologies, HVAC solutions and robotics, while creating innovative automotive and audio products through Harman. With its SmartThings ecosystem, open collaboration with partners, and integration of AI across its portfolio, Samsung delivers a seamless and intelligent connected experience. For the latest news, please visit the Samsung Newsroom at news.samsung.com.

LG Innotek Launches World’s First ‘Next-Generation Smart IC Substrate’

By
Advertorial Desk
-
  • Cuts carbon dioxide emissions from its production by 50%—equivalent to planting 1.3 million trees annually.
  • Boosts durability by up to three times for secure information recognition even with long-term use.
  • Mass production tailored to global customers starts in November, accelerating customer acquisition.

SEOUL, South Korea, Dec. 22, 2025 /PRNewswire/ — LG Innotek (CEO Moon Hyuksoo) announced on December 22 that the company has successfully developed a ‘Next-Generation Smart IC (integrated circuit) Substrate’ featuring enhanced performance and reducing carbon emissions generated in its production by half.

The smart IC substrate is an essential component for mounting IC chips that store information on smart cards, such as those in credit cards, electronic passports, and USIMs. When users place a smart card in an ATM or on a passport reader, the IC chip’s information is transmitted to the device via electronic signals.

  • Carbon emissions from its production cut by 50%, durability boosted by three times, and secure information recognition enabled

This ‘Next-Generation Smart IC Substrate’ is an eco-friendly product that reduces the carbon emissions generated in its production by half. The product will cut annual carbon dioxide emissions by 8,500 tons—equivalent to planting about 1.3 million trees, the company explained.

LG Innotek applied a new material to this product for the first time in the world, achieving high performance without precious metal plating processes.

Existing smart IC substrates require plating with precious metals such as palladium and gold (Au) on their surfaces. This process prevents corrosion where the substrate makes contact with readers and ensures effective electronic signal transmission.

However, the mining of palladium and gold generates massive amounts of greenhouse gases, and the prices of these metals remain high. Thus, the industry has sought new materials or processes to replace them. By eliminating surface plating, LG Innotek’s ‘Next-Generation Smart IC Substrate’ is thus attracting industry attention.

With environmental regulations tightening in Europe, home to major customers, LG Innotek is poised to gain a competitive edge in the global market with this ‘Next-Generation Smart IC Substrate.’

Furthermore, this product’s durability is three times greater than existing products. This minimizes information reading errors caused by wear from frequent external contact and long-term smart card use, delivering both higher performance and enhanced user convenience.

  • Mass production for global customers began in November, tailored to customer needs, accelerating customer acquisition

LG Innotek aims to accelerate its global market penetration with this ‘Next-Generation Smart IC Substrate’. In November, the company began mass production to supply leading global smart card manufacturers.

LG Innotek holds 20 domestic patents related to the ‘Next-Generation Smart IC Substrate’ and is pursuing patent registrations in the United States, Europe, and China. The company plans to secure additional global customers through active overseas promotions, leveraging its exclusive technology.

Cho Jitae(Jeffrey Cho), executive vice president and head of LG Innotek’s Package Solution Business, said: “The ‘Next-Generation Smart IC Substrate’ both satisfies customers’ ESG requirements and offers technological competitiveness. We will continue presenting innovative products that create differentiated customer value, making us a partner that realizes our customers’ visions.”

According to market research firm Mordor Intelligence, the global smart card market—currently valued at USD 20.3 billion—is projected to reach USD 30.6 billion by 2030, with an annual growth rate of 8.6%.

In particular, the smart card industry is increasingly adopting dual cards that support both insertion into devices and contactless transactions, boosting demand for replacing existing cards. Additionally, rising credit card issuance in emerging markets such as Africa and India is projected to drive continued growth in the smart card market.

[Glossary]

Smart card

A smart card is a card with a built-in IC chip that offers data storage, provides encryption, and transmits and receives electronic signals to and from readers for information authentication and payment. It is used across various sectors, including finance, transportation, and communication.

LG Innotek’s ‘Next-Generation Smart IC Substrate’
LG Innotek’s ‘Next-Generation Smart IC Substrate’

 

Samsung To Unveil AI Vision Built With Google Gemini at CES 2026

By
Advertorial Desk
-

With the upgraded AI Vision, Samsung becomes more fluent in food recognition and expands the reach of kitchen experiences

Company will also showcase a new Bespoke AI Wine Cellar and newly designed cooking appliances

SEOUL, South Korea, Dec. 22, 2025 /PRNewswire/ — Samsung Electronics Co., Ltd. today announced that it will unveil its latest kitchen appliances lineup at CES 2026, including the latest iterations of its Bespoke AI refrigerator, over-the-range (OTR) microwave, and slide-in range[1] at CES 2026. Alongside refreshed designs across the lineup, the company will highlight meaningful improvements to vision-based AI functionality enhanced with Google Gemini and Google Cloud, showing how these innovations simplify everyday tasks and elevate the overall kitchen experience.

“In pioneering the application of vision-based AI technology, Samsung has led innovation in the kitchen appliance market,” said Jeong Seung Moon, Executive Vice President and Head of R&D Team for Digital Appliances (DA) Business at Samsung Electronics. “Samsung will reach a new level of innovation through this collaboration with Google Cloud and will utilize these ongoing initiatives to continue to deliver better consumer experiences in the upcoming year.”

Introducing Samsung’s Latest AI Vision–Equipped Refrigerator

At CES, Samsung will present a new Bespoke AI Refrigerator Family Hub, equipped with the upgraded AI Vision. The feature’s key upgrade is its functions built with Google Gemini, which marks the first time that it is being integrated into a refrigerator.

Previously, it could recognize up to 37 types of fresh food and 50 types of pre-registered processed food on-device.[2] The latest version ready to be unveiled at CES is built to unlock its existing limitations to recognize more food items, offering a comprehensive and flexible experience.

It is planned to even recognize processed foods without separate registration, automatically registering their names to increase convenience. Additionally, Samsung aims to make it detect user-labeled items, foods stored in personal containers can be added to the food list.

With ingredients being identified more accurately, managing the food list becomes clearer and easier than before, broadening people’s food-related experiences. At CES, Samsung plans to showcase the enhanced capabilities and new use cases of AI Vision, demonstrating the future of a truly personalized AI kitchen.

 

Bespoke AI Refrigerator Family Hub
Bespoke AI Refrigerator Family Hub

 

Enhanced Wine Management With the New Samsung Bespoke AI Wine Cellar

Samsung will exhibit the new Bespoke AI Wine Cellar, designed to incorporate an AI Vision built with Google Gemini similar to that of the Bespoke AI Refrigerator.[3]

When users store or remove wine bottles from the wine cellar, a camera positioned at the top of the unit will recognize the labels and tracks bottles, updating the SmartThings AI Wine Manager[4] accordingly. The system will also be able to distinguish the specific shelf and compartment where each bottle is placed, allowing users to easily check locations without searching manually. Through the AI Wine Manager, users will be able to look up wine information more conveniently and receive suggestions on pairings based on the type of wine in their inventory, making wine curation more intuitive and personalized.

 

Bespoke AI Wine Cellar
Bespoke AI Wine Cellar

 

Unified Kitchen Aesthetic With an Upgraded Stainless Look   

Samsung is also introducing a lineup of French Door refrigerators, slide-in ranges and new OTR microwave models, offering consumers an updated aesthetic and a cohesive stainless-look option for creating a unified kitchen design.

The new Bespoke AI 3-Door French Door refrigerator features a zero clearance fit, which can be installed with side gaps of approximately 4mm.[5] Additionally, its door depth has been reduced by 50mm compared to the conventional 3-Door model,[6] enabling full access to drawers and food items with the doors wide open.[7] The AutoView — a transparent door — allows users to easily check items stored in the fridge.

The upgraded slide-in range features a completely refreshed design with a stainless-look finish across the control panel, knobs and door. It adopts a new bar handle style, along with a Precision Knob that provides enhanced safety.

Samsung will unveil two different types of OTR microwaves: the Air-Fry OTR and the DualVent OTR. The most significant change comes from the revised hood structure of the DualVent model. Typically, the depth of a cooktop on the range extends farther than that of an OTR, making it difficult for the hood to capture smoke from the front burners. Samsung’s new dual vent system addresses this by adding a front ventilation wing in addition to the bottom ventilation, significantly improving the capture rate compared to the previous model.

Visitors at Samsung’s booth at CES 2026 will be the first to see these new innovations. Learn more about Samsung’s CES activities here.

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, digital signage, smartphones, wearables, tablets, home appliances and network systems, as well as memory, system LSI and foundry. Samsung is also advancing medical imaging technologies, HVAC solutions and robotics, while creating innovative automotive and audio products through Harman. With its SmartThings ecosystem, open collaboration with partners, and integration of AI across its portfolio, Samsung delivers a seamless and intelligent connected experience. For the latest news, please visit the Samsung Newsroom at news.samsung.com

[1] This article contains products and features currently in development. The plans, timelines, and specifications described are forward-looking and subject to change without notice. Their future availability is not guaranteed.

[2] As of April 2025, AI Vision can recognize 37 food items like fresh fruits and vegetables. If the food is not recognizable, it may be listed as an unknown item. AI Vision cannot identify or list any food items in the fridge door bins or freezer. It recognizes food items based on deep learning models, which may be updated periodically to improve accuracy. AI Vision also recognizes packaged food items that have been saved by the user, and up to 50 items can be saved with designated names. Packaged items are limited to those that keep a certain packaged form.

[3] The recognition functionality is only available for shelves with withdrawal capability. For wine input and output, the label must be exposed to the top camera for proper recognition. Additionally, the multi-pantry drawer provides food storage functionality, and information about the food items stored in these drawers is provided as a separate image.

[4] Available on Android and iOS devices. A Wi-Fi connection and a Samsung account are required. Both devices must be signed in with the same Samsung account.

[5] Minimum required installation space for a custom built-in setup: [Width] 916 mm or more (Ensure a minimum gap of 4 mm on the left/right sides), [Height] 1798 mm or more (Ensure a minimum gap of 20 mm at the top).

[6] Compared to our conventional model without zero clearance fit feature (RF32CG5400**)

[7] The refrigerator door can be open up to 108°, but it depends on the installation environment.

Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions

By
Advertorial Desk
-

MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides a precision medicine portfolio update in relation to:

  • TLX591-CDx (Illuccix® in approved jurisdictions, 68Ga-PSMA-11): Positive data from Phase 3 study in Chinese patients provides the basis for near-term NDA submission in China.
  • TLX101-CDx (Pixclara®[1], 18F-floretyrosine), PET imaging candidate for glioma: Following collaborative interactions with the FDA, finalizing NDA resubmission and expect to provide a further near-term update on FDA acceptance of the file.
  • TLX250-CDx (Zircaix®[1], 89Zr-DFO-girentuximab), PET imaging candidate for ccRCC: Positive Type A meeting held with the FDA to align on remediation of CMC deficiencies identified in the CRL.

Further details on each of these updates is provided below.

Illuccix China Phase 3 Registration Study

Telix is pleased to announce positive top-line results from its Phase 3 registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11) for prostate cancer imaging in Chinese patients. The Illuccix China[2] trial met its primary endpoint of patient-level positive predictive value (PPV) for the detection of tumors in patients with biochemical recurrence (BCR) of prostate cancer following prior radical prostatectomy or radiation therapy. The study confirms that the clinical experience of TLX591-CDx PSMA-PET[3] imaging in Chinese patients is comparable to that observed in patients studied elsewhere.

Illuccix China is a Phase 3 prospective, open-label, single-arm, multicenter study conducted in collaboration with Telix’s strategic commercial partner for the Greater China region, Grand Pharmaceutical Group Limited (Grand Pharma). The study in 140 patients delivered a strong result for the primary endpoint, with an overall patient-level PPV of 94.8% for the detection of tumors with TLX591-CDx (95% confidence interval [CI]: 85.9%, 98.2%), with the lower bound of the 95% CI (85.9%). The region-level PPV was 100.0% in the prostate bed and in the extra-pelvic soft tissue, lymph nodes, and organ metastases (non-bone); 94.7% in the pelvic region outside of the prostate bed, including lymph nodes; and 87.0% in bone metastases.

In the study, patients with suspected BCR were stratified into groups according to their baseline prostate specific antigen (PSA) levels. TLX591-CDx PSMA-PET imaging demonstrated high PPV in all patient groups, including at very low baseline PSA levels.

Baseline PSA

PPV (95% CI)

≥ 5.0 ng/mL

100.0% (78.5%, 100.0%)

< 5.0 to 2.0 ng/mL

100.0% (67.6%, 100.0%)

< 2.0 to 1.0 ng/mL

90.9% (62.3%, 98.4%)

< 1.0 to 0.5 ng/mL

90.0% (59.6%, 98.2%)

< 0.5 to 0.2 ng/mL

93.3% (70.2%, 98.8%)

More than two-thirds (67.2%) of patients experienced a change in their treatment plan as a consequence of TLX591-CDx PSMA-PET imaging compared with the initial plan at baseline. This outcome confirms that PSMA-PET imaging with TLX591-CDx had a meaningful impact on clinical decision-making in Chinese patients, potentially leading to improved treatment strategies for participants with BCR. Final data from the study will be submitted for peer-reviewed publication.

Dr. David N. Cade, Group Chief Medical Officer, Telix, commented, “This is an outstanding result. The primary endpoint of the study was met decisively, with the positive predictive value significantly exceeding the performance threshold agreed with the Chinese regulator. Importantly, the high PPV was consistent even in patients with very low PSA values, and across differing metastatic locations, demonstrating broad clinical applicability. These compelling data will enable Telix and our partner Grand Pharma to submit a New Drug Application for Illuccix in China, a strategically important market.”

In China, more than 134,000 men were diagnosed with prostate cancer in 2022[4], increasing by approximately 6% each year[5]. In line with government policy supporting wider geographic access to nuclear medicine, the number of PET/CT cameras installed in China is expected to surpass 1,600 by the end of 2025[6], compared with 133 in 2010[7].

FDA Resubmission Update: TLX101-CDx

Telix advises that its New Drug Application (NDA) resubmission for TLX101-CDx, (Pixclara®[1], 18F-floretyrosine) to the United States (U.S.) Food and Drug Administration (FDA), is progressing well. The Company has had collaborative interactions with the FDA around providing additional clinical data and a revised statistical analysis plan.

Following a productive Type A meeting to review the basis of the Complete Response Letter (CRL)[8], Telix is currently finalizing its package for resubmission. The Company will provide a further near-term update when the resubmission has been filed and accepted by the FDA. The approved Expanded Access Program (EAP)[9] remains active for TLX101-CDx, reflective of Telix’s commitment to serving patients.

FDA Resubmission Update: TLX250-CDx

Telix has recently participated in a Type A meeting to discuss the CRL it received following review of the Biologics License Application (BLA)[10] for TLX250-CDx (Zircaix®[1], 89Zr-DFO-girentuximab). Telix believes it has reached alignment with the FDA on the remediation of identified deficiencies regarding the product’s chemistry, manufacturing, and controls (CMC) package, which formed the substantive basis of the CRL.

The FDA has collaboratively granted Telix an additional meeting in January to review Telix’s plan for the additional data requested to establish comparability between the drug product used in the ZIRCON Phase 3 clinical trial[11] and the scaled-up manufacturing process intended for commercial use. Telix will provide a further update following receipt of the official FDA meeting minutes of both Type A meetings. The approved Expanded Access Program (EAP)[12] remains active for TLX250-CDx, reflective of Telix’s commitment to serving patients.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the U.S. FDA[13].

TLX101-CDx is Telix’s PET imaging candidate for glioma, a rare and life-threatening brain cancer. TLX250-CDx is Telix’s PET imaging candidate for the diagnosis and characterization of clear cell renal cell carcinoma, the most common kidney cancer subtype. TLX101-CDx and TLX250-CDx have not received a marketing authorization in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook

Telix Investor Relations (Global)

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.)

Annie Kasparian 
Telix Pharmaceuticals Limited 
Director Investor Relations and Corporate Communications 
Email: annie.kasparian@telixpharma.com 

Media Contact

Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-CDx and the planned BLA resubmission for TLX250-CDx, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2025 Telix Pharmaceuticals Limited. All rights reserved.

[1] Brand name subject to final regulatory approval.

[2] ClinicalTrials.gov ID: NCT05847348.

[3] Imaging of prostate-specific membrane antigen with positron emission tomography.

[4] Global Cancer Statistics 2022: GLOBOCAN survey. Published August 2024.

[5] Ye Dingwei et al. Lancet Oncology, 2022.

[6] Yang et al. J Nuc. Med. 2024.

[7] Goetz Partners research 2020.

[8] Telix ASX disclosure 28 April 2025.

[9] ClinicalTrials.gov ID: NCT06743100.

[10] Telix ASX disclosure 28 August 2025.

[11] ClinicalTrials.gov ID: NCT03849118.

[12] ClinicalTrials.gov ID: NCT06090331.

[13] Telix ASX disclosure 21 March 2025.

 

T-MAXIMUM Pharmaceutical’s Allogeneic CAR-T Therapy MT027 Receives FDA IND Clearance to Proceed to Phase II clinical Trial for Recurrent Glioblastoma

By
Advertorial Desk
-

BEIJING, Dec. 21, 2025 /PRNewswire/ — T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial for the treatment of recurrent glioblastoma (rGBM). This milestone marks a significant breakthrough in addressing one of the most formidable challenges in oncology: developing effective allogeneic CAR-T therapies for solid tumors.

“The FDA’s clearance of the IND for MT027 represents a strong validation of our strategic commitment to tackling the most challenging solid tumors,” said Dr. Xiaoyun Shang, Founder and CEO of T-MAXIMUM Pharmaceutical. “This milestone is not only a small step for T-MAXIMUM, but a significant leap forward for the entire cell therapy field as we push into the ‘uncharted territory’ of solid tumor treatment. The successful development and advancement of MT027 is grounded in our deep understanding of immunology and our decisive investment in allogeneic cell-editing technologies. As a technology-driven company, T-MAXIMUM Pharmaceutical will continue to uphold a rigorous and pragmatic scientific approach, steadily advancing the clinical development of MT027. We remain committed to breaking new ground in the unexplored landscape of solid tumor cell therapy and using the power of science to win more time for patients.”

About MT027

MT027 is an “off-the-shelf” allogeneic CAR-T product sourced from healthy donors and designed to target B7-H3 for the treatment of recurrent glioblastoma. As an allogeneic therapy, MT027 enables large-scale manufacturing and cryopreservation, allowing patients to receive treatment rapidly without the delays associated with autologous cell production—an advantage that can be critical for individuals facing fast-progressing and life-threatening diseases.

Unlike many industry peers relying on lentiviral or retroviral vectors, T-MAXIMUM Pharmaceutical has achieved a major advancement during the product’s transition to registration-oriented clinical development—establishing a fully non-viral gene-editing platform. This innovation enhances product safety while improving manufacturing precision and controllability, representing the next generation of cell therapy engineering.

CAR-T therapies have revolutionized treatment for hematologic malignancies; however, progress in solid tumors has been notably slower—particularly in glioblastoma, where the blood-brain barrier, intratumoral heterogeneity, and immunosuppressive microenvironment pose unique challenges. FDA IND clearance enabling MT027 to enter Phase II clinical evaluation represents a milestone step in advancing allogeneic CAR-T technology toward one of the most difficult solid tumor indications.

Leveraging its mature allogeneic technology platform, T-MAXIMUM Pharmaceutical is concurrently developing additional clinical programs targeting brain metastases and other solid tumors, further expanding its therapeutic pipeline.

About Glioblastoma

Glioblastoma (GBM) is among the most aggressive and lethal cancers of the central nervous system, often referred to as the “Mount Everest” of neurosurgery. Despite widespread adoption of the standard Stupp regimen, median overall survival remains only 14–16 months, with a five-year survival rate below 5%. For patients with recurrent glioblastoma, treatment options are even more limited, with median survival typically less than 6–9 months. There remains a profound unmet medical need in this area.

Since its founding, T-MAXIMUM Pharmaceutical has focused its research and development strategy on addressing these unmet needs, deliberately steering away from highly competitive hematologic indications to confront the formidable challenge of glioblastoma. This regulatory achievement validates the feasibility and potential of the company’s platform.

About T-MAXIMUM Pharmaceutical

T-MAXIMUM Pharmaceutical is an innovative biotechnology company dedicated to the development of allogeneic, off-the-shelf cell therapies, with a mission to address diseases for which there are currently no effective treatments. The company brings together a seasoned team with expertise in immunotherapy, gene editing, and biopharmaceutical industrialization. Leveraging its fully proprietary gene-edited allogeneic immune cell platform, T-MAXIMUM has successfully overcome key challenges in allogeneic cell therapy, including graft-versus-host disease (GvHD) and immune rejection, enabling durable in-vivo persistence and therapeutic efficacy of CAR-T cells.

T-MAXIMUM is currently focused on late-stage malignant tumors, and its lead program for recurrent glioma has received clearance to enter Phase II clinical trials. Over the next three years, the company aims to advance at least one product toward marketing approval and progress multiple programs into Phase II clinical development.

Guided by the principles of integrity, innovation, and collaborative excellence, T-MAXIMUM Pharmaceutical remains committed to clinical value and original innovation. The company continues to pioneer breakthroughs in solid tumor cell therapy, striving to bring new hope to patients with diseases lacking effective treatment options.

1...1,6571,6581,659...6,695Page 1,658 of 6,695